Happy Health has raised $75m as it eyes adding more use cases to its at-home health monitoring platform beyond an initial focus on obstructive sleep apnoea (OSA).
The Texas-based company’s financing round was led by ARCH Venture Partners and OpenLoop and will support the advance of Happy Ring, the company’s smart ring for OSA diagnosis, given the company’s view that sleep is “one of the richest windows into human physiology”.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Looking ahead, Happy Health highlighted its expectation that its platform will eventually support earlier physician-guided detection and management across cardiovascular, metabolic, and other chronic diseases. It is unclear whether new devices will be developed to support these additional indications.
US Food and Drug Administration (FDA)-cleared in June 2025 for OSA diagnosis, Happy Health’s smart ring is designed to diagnose the condition within several nights by monitoring a range of biometric parameters and analysing them with AI. The digital health company’s smart ring had gained an initial clearance for general biometric monitoring in September 2024.
Research from 2024 indicates that over 83 million people in the US have sleep apnoea. However, nearly 80% of Americans with OSA remain undiagnosed, despite the condition’s established links to pathologies including hypertension, cardiovascular disease, stroke, and metabolic disorders.
Reflecting on its first clinical focus of OSA, Happy Health’s CEO, Dustin Freckleton, told Medical Device Network: “What we’ve built in sleep is the foundation for a much bigger vision: continuously monitoring patients at home to detect disease earlier and give physicians the opportunity to intervene before it becomes more serious.
“The funds will help us accelerate toward this goal, strengthening the tech, while building out the clinical validation and infrastructure to take our capabilities beyond sleep.”
In raising awareness about its product, Freckleton highlighted that the biggest challenge lies in getting people to understand that the company’s offering is not “just another health tracker”.
He continued: “That’s a natural assumption because products like Oura have defined what consumers expect from a ring. Oura built a fantastic wellness product and proved that people care about sleep. We’re building something entirely different: a clinical-grade health platform that happens to fit on your finger. Our focus now is expanding what that platform can detect, strengthening the clinical evidence behind it, and connecting those insights to physician-guided care.”
GlobalData analysis reveals that the global patient monitoring market is growing at a compound annual growth rate (CAGR) of 1.9% and is forecast to reach a valuation of around $25.4bn in 2035, up from around $21bn in 2025.
